Background: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. Method: This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. Results: A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). Conclusions: Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.

Incorvaia, L., Monteiro, F.S.M., Massari, F., Park, S.H., Roviello, G., Fiala, O., et al. (2024). Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 73(8), 1-12 [10.1007/s00262-024-03719-0].

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Massari, Francesco;
2024

Abstract

Background: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. Method: This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. Results: A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). Conclusions: Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
2024
Incorvaia, L., Monteiro, F.S.M., Massari, F., Park, S.H., Roviello, G., Fiala, O., et al. (2024). Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 73(8), 1-12 [10.1007/s00262-024-03719-0].
Incorvaia, Lorena; Monteiro, Fernando Sabino Marques; Massari, Francesco; Park, Se Hoon; Roviello, Giandomenico; Fiala, Ondřej; Myint, Zin W; Kucharz, Jakub; Molina-Cerrillo, Javier; Santini, Daniele; Buttner, Thomas; Poprach, Alexandr; Kopecky, Jindrich; Zeppellini, Annalisa; Pichler, Martin; Buchler, Tomas; Pichler, Renate; Facchini, Gaetano; Fay, Andre Poisl; Soares, Andrey; Manneh, Ray; Iezzi, Laura; Kuronya, Zsofia; Russo, Antonio; Bourlon, Maria T; Bhuva, Dipen; Ansari, Jawaher; Kanesvaran, Ravindran; Grande, Enrique; Buti, Sebastiano; Santoni, Matteo
File in questo prodotto:
File Dimensione Formato  
Cancer Immunol Immunotherapy [ARON-1 F:M].pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.49 MB
Formato Adobe PDF
1.49 MB Adobe PDF Visualizza/Apri
262_2024_3719_MOESM1_ESM.docx

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 140.66 kB
Formato Microsoft Word XML
140.66 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/971115
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact